Previous 10 | Next 10 |
home / stock / lmllf / lmllf news
Committed to the 'pipeline-in-a-pill' approach with PD-001 for certain cancers and COVID-19 Advances cGMP manufacturing of clinical drug supply with Southwest Research Institute Receives final positive data for recently conducted prostate cancer model and evaluates opportunities to b...
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: NIO, Inc. (NYSE:NIO), PharmaDrug (OTC: LMLLF) (CSE: PHRX), NuRAN Wireless (OTC: NRRWF) (CSE: NUR) and SoF...
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Moderna, Inc. (NASDAQ: MRNA), PharmaDrug (OTC: LMLLF) (CSE: PHRX) Tilray, Inc. (NASDAQ:TLRY) and ...
Interim results show that oral cepharanthine plus cabazitaxel (combination therapy) significantly reduced tumor volume and increased tumor growth inhibition at day 21, the final day of dosing Dose range findings demonstrate that oral cepharanthine-alone was well tolerated in the current i...
PharmaDrug receives encouraging potency data for candidate DMT-analogue molecules designed to treat primary open angle glaucoma Terasaki Institute advances PharmaDrug's candidate DMT-analogue molecules into next phase of potency/kinetics study Terasaki Institute initiates fabrication ...
Patent claims on synergistic application of cepharanthine, cabazitaxel and other taxane family members used in combination to treat primary, metastatic and chemotherapy-resistant prostate cancer Expands on Company's 'pipeline in a pill' strategy with cepharanthine in treating rare cancers ...
Establishing cGMP supply for IND-enabling and up to Phase 2 clinical studies for PD-001 oral formulation for esophageal cancer and mild to moderate COVID-19 Toronto, Ontario--(Newsfile Corp. - January 26, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), ...
Toronto, Ontario--(Newsfile Corp. - January 24, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (FSE: G111) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psyched...
Toronto, Ontario--(Newsfile Corp. - January 20, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, canna...
Toronto, Ontario--(Newsfile Corp. - January 13, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTC: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabi...
News, Short Squeeze, Breakout and More Instantly...
2024-05-23 11:51:50 ET This company believes that the only viable way to produce a safe supply of street drugs is to develop biosynthetic versions of these substances to be manufactured domestically in a regulated %Pharmaceutical supply chain. The signing of a recent LOI could potential...
Toronto, Ontario--(Newsfile Corp. - May 23, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved...
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent ...